Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial read-outs, shelf registrations, and sudden capital raises make Bicara Therapeutics鈥� SEC disclosures anything but straightforward. If you have ever searched a 300-page prospectus just to find cash-runway details, you know the challenge.
Our platform solves that problem. Stock Titan鈥檚 AI instantly converts dense language into plain-English highlights, letting you understand Bicara Therapeutics SEC documents with AI instead of slogging through technical jargon. Need the latest 8-K material events explained or the most recent Bicara Therapeutics quarterly earnings report 10-Q filing? Every form appears here in real time, tagged and summarized.
Here鈥檚 how analysts, portfolio managers, and biotech followers use this page:
- Track Bicara Therapeutics insider trading Form 4 transactions and receive alerts on executive stock transactions Form 4 moments after they hit EDGAR.
- Compare R&D spend, dilution risk, and cash burn with our AI-layered Bicara Therapeutics annual report 10-K simplified notes.
- Dive into pipeline progress via Bicara Therapeutics 8-K material events explained, including interim data disclosures for ficerafusp alfa.
- Review compensation packages through the Bicara Therapeutics proxy statement executive compensation section without hunting across exhibits.
Whether you鈥檙e screening biotech investments or verifying a single clinical milestone, our comprehensive coverage鈥�10-K, 10-Q, S-1, 8-K, and Bicara Therapeutics Form 4 insider transactions real-time鈥攌eeps you ahead of market-moving details. No more page-count anxiety; the insights you need are surfaced instantly, ready for decisive action.
Schedule 13G/A (Am. No. 1) filed for Bicara Therapeutics Inc. (BCAX) shows that investment entities affiliated with Invus have built a passive 9.6 % stake in the company鈥檚 common stock as of 30 Jun 2025.
- Invus Public Equities, L.P. directly owns 4,861,944 shares (8.9 %).
- Avicenna Life Sci Master Fund LP holds 355,025 shares (0.7 %).
- Through control of multiple GP/LLC vehicles, Raymond Debbane is deemed to beneficially own a combined 5,216,969 shares, representing the full 9.6 %.
Percentages are based on 54,536,218 shares outstanding reported in the issuer鈥檚 13 May 2025 10-Q. The filing is made under Rule 13d-1(c) and includes the standard certification that the securities were not acquired to change or influence control, indicating a passive investment approach.
The appearance of a sophisticated life-sciences investor just below the 10 % threshold may improve market confidence and liquidity but does not signal activist intent at this stage.
Bicara Therapeutics Inc. (BCAX) 鈥� Form 4 insider filing dated 18 Jun 2025 reports transactions by Chief Legal Officer Lara Meisner.
Non-derivative activity: On 16 Jun 2025 Meisner exercised 15,829 options for common stock at an exercise price of $5.45 per share and immediately sold the same 15,829 shares at a weighted-average price of $10.43 (individual sales executed between $10.03-$10.84). As a result, her direct common-stock ownership fell to 0 shares.
Derivative holdings: Two option grants were partially exercised. After the transactions Meisner still directly holds 60,854 options with a $5.45 strike expiring 10 Dec 2033 and 97,443 options with the same strike and expiry, for a total of 158,297 remaining options.
- Grant #1 vests in 16 equal quarterly installments from 14 Dec 2023.
- Grant #2 vested 25 % on 27 Nov 2024; the balance vests in 12 equal quarterly installments thereafter.
Rule 10b5-1 plan: All trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on 13 Nov 2024, as disclosed in the Explanation of Responses.
The filing reflects routine option exercise and monetisation by an executive officer, with no change to derivative exposure but the elimination of directly held common shares.
FAQ
What is the current stock price of Bicara Therapeutics (BCAX)?
What is the market cap of Bicara Therapeutics (BCAX)?
